<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02873156</url>
  </required_header>
  <id_info>
    <org_study_id>E2027-A001-002</org_study_id>
    <nct_id>NCT02873156</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2027 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2027 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and
      pharmacokinetics (PK) of multiple ascending oral doses of E2027 in healthy participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum drug concentration (Cmax)</measure>
    <time_frame>Day 1 and Day 14</time_frame>
    <description>Blood samples will be collected on Day 1 at predose and postdose 0.5 (30 minutes), 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 18 hours; Day 14 (at predose and postdose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 18 hours); and Day 15 (24 hours postdose from Day 14).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean predose drug concentration (Cmin)</measure>
    <time_frame>Predose on Days 2, 4, 6, 8, 10, 12, 13, and 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean time to reach maximum (peak) drug concentration (tmax)</measure>
    <time_frame>Day 1 and Day 14</time_frame>
    <description>Blood samples will be collected on Day 1 at predose and postdose 0.5 (30 minutes), 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18 and 24 hours; Day 14 (at predose and postdose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 18 hours); and Day 15 (24 hours postdose from Day 14).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean area under the concentration-time curve from zero time to 24 hours postdose (AUC(0-24h))</measure>
    <time_frame>Day 1 and Day 14</time_frame>
    <description>Blood samples will be collected on Day 1 at predose and postdose 0.5 (30 minutes), 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18 and 24 hours; Day 14 (at predose and postdose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 18 hours); and Day 15 (24 hours postdose from Day 14).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean area under the concentration-time curve from zero time extrapolated to infinity (AUC(0-inf))</measure>
    <time_frame>Day 14</time_frame>
    <description>Blood samples will be collected on Day 14 (at predose and postdose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 18 hours) and Day 15 (24 hours postdose from Day 14).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean terminal elimination half-life (t1/2)</measure>
    <time_frame>Day 14</time_frame>
    <description>Blood samples will be collected on Day 14 (at predose and postdose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 18 hours) and Day 15 (24 hours postdose from Day 14).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average steady state drug concentration (Css,av)</measure>
    <time_frame>Day 14</time_frame>
    <description>Blood samples will be collected on Day 14 (at predose and postdose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 18 hours) and Day 15 (24 hours postdose from Day 14).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean apparent clearance at steady state (CLss/F)</measure>
    <time_frame>Day 14</time_frame>
    <description>Blood samples will be collected on Day 14 (at predose and postdose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 18 hours) and Day 15 (24 hours postdose from Day 14).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean apparent volume of distribution at steady state (Vss/F)</measure>
    <time_frame>Day 14</time_frame>
    <description>Blood samples will be collected on Day 14 (at predose and postdose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 18 hours) and Day 15 (24 hours postdose from Day 14).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean accumulation ratio (Rac) (Day 14: Day 1) for AUC(0-24h), Cmax and Cmin</measure>
    <time_frame>Day 1 and Day 14</time_frame>
    <description>Day 1 at predose and postdose 0.5 (30 minutes), 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 18 and 24 hours; Day 14 (at predose and postdose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 18 hours); and Day 15 (24 hours postdose from Day 14)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean peak-trough fluctuation ratio (PTF)</measure>
    <time_frame>Day 14</time_frame>
    <description>Blood samples will be collected on Day 14 (at predose and postdose 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, and 18 hours) and Day 15 (24 hours postdose from Day 14).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean ratio of cerebrospinal fluid (CSF) : plasma concentrations</measure>
    <time_frame>Day -2 (time-matched to the Day 13 lumbar puncture [LP]) and Day 13 (predose)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage change from Baseline in pharmacodynamic measure</measure>
    <time_frame>Day -2 (baseline with no drug) to Day 13 (on drug)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Observed Fridericia's Correction Formula (QTcF)</measure>
    <time_frame>Days -1, 1, and 14</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>E2027</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four sequential cohorts of healthy participants (≥50 years and ≤85 years old) will be treated with multiple ascending doses of E2027 up to the maximum tolerated dose (MTD). A total of 6 participants per cohort will be randomized to E2027.Proposed doses of E2027 are:
Part A Cohort 1: 50 mg (1 × 50 mg capsule)
Cohort 2: 100 mg (2 × 50 mg capsules)
Cohort 3: 200 mg (4 × 50 mg capsules)
Cohort 4: 400 mg (8 × 50 mg capsules)
Cohort 6: 25 mg (5 × 5 mg capsules) Part B
Cohort 5: 400 mg (8 × 50 mg capsule)
Part C:
• Cohort 7: 50 mg (1 × 50 mg capsules)
Part D:
Cohort 8: 5 mg (1 × 5 mg capsules)
Cohort 9: 10 mg (2 × 5 mg capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Four sequential cohorts of healthy participants (≥50 years and ≤85 years old) will be treated with multiple ascending doses of E2027 matched placebo up to the MTD. A total of 2 participants per cohort will be randomized to E2027 matched placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2027</intervention_name>
    <description>Participants will receive E2027 capsules, orally once daily (QD) on Days 1 to 14 after an overnight fast of at least 10 hours. E2027 will be administered orally with 240 milliliter (mL) (8 fluid ounces) of water.</description>
    <arm_group_label>E2027</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E2027 matched placebo</intervention_name>
    <description>Participants will receive E2027 matched placebo capsules, orally once daily (QD) on Days 1 to 14 after an overnight fast of at least 10 hours. E2027 matched placebo will be administered orally with 240 mL (8 fluid ounces) of water.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria Parts A, B,C and D

        1. Nonsmoking, male or female, age ≥50 years and ≤85 years old at the time of informed
        consent 2. Body mass index (BMI) ≥18 and ≤32 kilogram per square meter (kg/m2) at Screening
        Part B 3. Born in Japan to Japanese parents and grandparents of Japanese descent 4.
        Lifestyle, including diet, has not changed significantly since leaving Japan Exclusion
        Criteria

          1. Clinically significant illness that requires medical treatment within 8 weeks or a
             clinically significant infection that requires medical treatment within 4 weeks of
             dosing

          2. Females who are breastfeeding or pregnant at Screening or Baseline (documented by a
             negative beta-human chorionic gonadotropin [beta (ß)-hCG] (or human chorionic
             gonadotropin [hCG]) test with a minimum sensitivity of 25 International Unit per Liter
             (IU/L) or equivalent units of ß-hCG [or hCG]). A negative urine pregnancy test is
             required before the administration of the 1st dose per cohort.

          3. Females of childbearing potential who:

               -  Had unprotected sexual intercourse within 30 days before study entry and do not
                  agree to use a highly effective method of contraception (eg, total abstinence, an
                  intrauterine device, a double barrier method [such as condom plus diaphragm with
                  spermicide] or have a vasectomized partner with confirmed azoospermia but
                  hormonal contraceptives are not permitted) throughout the entire study period and
                  for 28 days after study drug discontinuation

               -  Are currently abstinent, and do not agree to use a double barrier method (as
                  described above) or refrain from sexual activity during the study period or for
                  28 days after study drug discontinuation NOTE: All females will be considered to
                  be of childbearing potential unless they are postmenopausal (amenorrheic for at
                  least 12 consecutive months, in the appropriate age group, and without other
                  known or suspected cause) or have been sterilized surgically (ie, bilateral tubal
                  ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at
                  least 1 month before dosing).

          4. Males who have not had a successful vasectomy (confirmed azoospermia) or they and
             their female partners do not meet the criteria above (ie, not of childbearing
             potential or practicing highly effective contraception throughout the study period or
             for 28 days after study drug discontinuation). No sperm donation is allowed during the
             study period or for 28 days after study drug discontinuation

          5. Medical conditions which are not adequately and stably controlled on stable doses of
             medications or which, in the clinical opinion of the Principal Investigator (PI), may
             interfere with study procedures or participant safety within 4 weeks before dosing
             (eg, psychiatric disorders and disorders of the gastrointestinal tract, liver, kidney,
             respiratory system, endocrine system, hematological system, neurological system, or
             cardiovascular system, or participants who have a congenital abnormality in
             metabolism). Participants with the following stable medical conditions, adequately
             controlled with stable doses of concomitant medications, need not be excluded if in
             the opinion of the PI, their conditions do not compromise participant safety or study
             procedures:

               -  hypertension without cerebrovascular or cardiovascular complications, controlled
                  on not more than 1 antihypertensive drug

               -  hyperlipidemia without cerebrovascular or cardiovascular complications,
                  controlled with diet or monotherapy medication

               -  mild, localized diseases of the skin, respiratory tract which do not require
                  systemic medication treatment and without systemic complications

               -  mild, localized diseases of the eyes which are not symptomatic and do not require
                  systemic medication treatment and without systemic complications

               -  osteoarthritis which does not require opioids for treatment of pain

          6. History of cerebrovascular disease (including transient ischemic attack or stroke)

          7. Any history of abdominal surgery that may affect pharmacokinetic (PK) profiles of
             E2027 (eg, hepatectomy, nephrectomy, digestive organ resection) at Screening or
             Baseline

          8. Any other clinically abnormal symptom or organ impairment found by medical history,
             physical examinations, vital signs, electrocardiogram (ECG) finding, or laboratory
             test results that requires medical treatment at Screening or Baseline

          9. A prolonged QT/QTc interval (QTc &gt;450 millisecond [ms]) demonstrated on ECG at
             Screening or Baseline (based on average of triplicate ECGs). A history of risk factors
             for torsade de pointes (eg, heart failure, hypokalemia, family history of long QT
             Syndrome) or the use of concomitant medications that prolonged the QT/QTc interval

         10. Left bundle branch block at Screening or Baseline

         11. Persistent systolic blood pressure (BP) &gt;160 millimeter of mercury (mm Hg) or
             diastolic BP &gt;100 mm Hg at Screening or Baseline (based on BP measured on at least 3
             occasions over 2 weeks)

         12. Persistent heart rate (HR) less than 50 beats/minute (min) or more than 90 beats/min
             at Screening or Baseline (based on HR measured on at least 3 occasions over 2 weeks)

         13. History of myocardial infarction, ischemic heart disease or cardiac failure

         14. History of clinically significant arrhythmia or uncontrolled arrhythmia

         15. Known history of clinically significant drug allergy at Screening or Baseline

         16. Known history of food allergies or presently experiencing significant seasonal or
             perennial allergy at Screening or Baseline

         17. Known to be human immunodeficiency virus (HIV) positive at Screening

         18. Active viral hepatitis (A, B, or C) as demonstrated by positive serology at Screening

         19. History of drug or alcohol dependency or abuse within the 2 years before Screening, or
             those who have a positive urine drug or alcohol test at Screening or Baseline
             (participants whose positive urine drug test is considered by the investigator and
             sponsor medical monitor to be due to permitted concomitant medications need not be
             excluded)

         20. Participants who smoke or have used tobacco or nicotine-containing products within 4
             weeks before to dosing

         21. A Columbia Suicide Severity Rating Scale (C-SSRS) suicidal ideation score of 4 or 5 at
             Screening or Baseline or for the period within 6 months before to Screening or
             Baseline or any lifetime suicidal behavior

         22. Currently enrolled in another clinical study or used any investigational drug or
             device within 30 days (or 5 half-lives, whichever is longer) preceding informed
             consent

         23. Engagement in strenuous exercise within 2 weeks before check-in (eg, marathon runners,
             weight lifters)

         24. Any contraindications to cerebrospinal fluid (CSF) sampling by lumbar puncture (LP)

         25. Participants with platelet count &lt;60,000, international normalized ratio (INR) &gt;1.2,
             or partial thromboplastin time (PTT) &gt; upper limit of normal (ULN) at Screening

         26. Intake of caffeinated beverages or caffeinated food within 72 hours before dosing

         27. Intake of nutritional supplements, juice, and herbal preparations or other foods or
             beverages that may affect the various drug metabolizing enzymes and transporters (eg,
             alcohol, grapefruit, grapefruit juice, grapefruit-containing beverages, apple or
             orange juice, vegetables from the mustard green family [eg, kale, broccoli,
             watercress, collard greens, kohlrabi, brussel sprouts, mustard], and charbroiled
             meats) within 1 week before dosing

         28. Intake of herbal preparations containing St. John's Wort within 4 weeks before dosing.

         29. Intake of over-the-counter (OTC) medications within 14 days (or 5 half-lives,
             whichever is longer) before dosing unless the principal investigator and sponsor
             medical monitor consider that they do not compromise participant safety or study
             assessments

         30. Participants who are taking prohibited medications as listed in Concomitant
             Drug/Therapy section within 14 days before dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eisai Medical Information</last_name>
    <phone>1-888-274-2378</phone>
    <email>esi_medinfo@eisai.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>California Clinical Trials Medical Group</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2016</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>E2027</keyword>
  <keyword>Healthy participants</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

